Premium
Analysis of attitudes toward the source of progenitor cells in tissue‐engineered products for use in burns compared with other disease states
Author(s) -
Clover Anthony J. P.,
Lane O'Neill Billy,
Kumar Arun H. S.
Publication year - 2012
Publication title -
wound repair and regeneration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.847
H-Index - 109
eISSN - 1524-475X
pISSN - 1067-1927
DOI - 10.1111/j.1524-475x.2012.00779.x
Subject(s) - medicine , diabetes mellitus , disease , progenitor cell , intensive care medicine , dermatology , surgery , stem cell , genetics , endocrinology , biology
The first trials using progenitor cells to improve burn wound healing are beginning. However, there remains a paucity of data on patients' opinions of the source of stem cells. In this study, 279 patients attending plastic surgery/burns outpatient and medical outpatient clinics were questioned to assess willingness to accept a tissue‐engineered skin product derived from a variety of sources. Levels of acceptance for the use of progenitor cells derived from these sources for treatment across a range of disease states (burns, P arkinson's disease, diabetes, and for cosmetic use) were also assessed. Overall, 80% of those questioned would accept a tissue‐engineered product. Autologous cells were the preferred choice of cells (acute burns 94%, diabetes 95%, P arkinson's 93.9%). Allogeneic cells were still widely accepted (acute burns 67%, diabetes 66.7%, P arkinson's 69.2%). There was no difference observed between plastic surgical patients and medical patients in acceptance of cell therapy for burns, P arkinson's disease, or diabetes. There is good potential acceptance for the use of both autologous and allogeneic cells for the treatment of acute burns and burns' scarring as well as in diabetes and P arkinson's disease. Disease state does not appear to influence overall acceptability and choice of cells.